Article
Hematology
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.
Article
Business, Finance
Mathias Verreydt, Nico Dewaelheyns, Cynthia Van Hulle
Summary: This study contributes to the ongoing debate on the optimal design of reorganization procedures by analyzing the time-to-failure of unsuccessful reorganization cases in Belgium's insolvency system. The findings show that there are differences in time-to-failure determinants across procedure types, which align with the intentions of the legislator. However, the implementation of the flexible system has not significantly improved the lengthiness of procedures or the financial situation of applicants.
FINANCE RESEARCH LETTERS
(2022)
Article
Oncology
Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Kadia, Naveen Pemmaraju, Koji Sasaki, Marina Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey Jorgensen, Sa Wang, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop Kantarjian, Susan O'Brien, Michael Keating, William G. Wierda
Summary: The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation. The treatment resulted in high rates of complete remission and undetectable measurable residual disease in the marrow, with excellent 3-year progression-free and overall survival rates.
Article
Critical Care Medicine
Mahbod Rahimi, Paul Dorian, Sheldon Cheskes, Gerald Lebovic, Steve Lin
Summary: This study examined the association between time to treatment and survival and neurologic outcome. The findings showed that longer time to treatment was associated with decreased survival and favorable neurologic outcomes. Amiodarone improved survival at all time points, while lidocaine only improved survival at later time points compared to placebo.
CRITICAL CARE MEDICINE
(2023)
Article
Hematology
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D'Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Summary: The MURANO trial demonstrated that Venetoclax plus Rituximab is superior to Bendamustine plus Rituximab in terms of progression-free survival and overall survival in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study also found that undetectable minimal residual disease (uMRD) can be achieved more often with Venetoclax plus Rituximab, and the long-term implications of uMRD in this treatment regimen were explored.
Article
Oncology
Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, Jatin Shah, Michael G. Kauffman, Sharon Shacham, Bhavana Bhatnagar
Summary: Single-agent oral eltanexor showed good efficacy and tolerability in patients with higher-risk, primary HMA-refractory MDS.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Zaid Muslim, Stephanie Stroever, Syed S. Razi, Kostantinos Poulikidis, Mirza Zain Baig, Cliff P. Connery, Faiz Y. Bhora
Summary: The study aimed to investigate the predictors of increased time-to-treatment initiation in lung cancer patients in the United States using the National Cancer Database. The results showed that black race, a later year at diagnosis, nonprivate insurance, and diagnosis and treatment at different facilities were independent predictors of increased time-to-treatment initiation.
ANNALS OF THORACIC SURGERY
(2023)
Article
Hematology
Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt
Summary: The CLL-IPI is effective in predicting disease progression and survival rates of chronic lymphocytic leukemia patients, with B-cell count being a significant factor in these predictions.
Editorial Material
Hematology
Carol Moreno, Alba Mora
Summary: This study compares the MRD rates and outcomes of CLL patients treated with different regimens, providing valuable insights into the management of CLL.
Article
Hematology
Riccardo Moia, Lodovico di Terzi Bergamo, Donatella Talotta, Riccardo Bomben, Gabriela Forestieri, Valeria Spina, Alessio Bruscaggin, Chiara Cosentino, Mohammad Almasri, Riccardo Dondolin, Tamara Bittolo, Antonella Zucchetto, Stefano Baldoni, Ilaria Del Giudice, Francesca Romana Mauro, Rossana Maffei, Annalisa Chiarenza, Agostino Tafuri, Roberta Laureana, Maria Ilaria Del Principe, Francesco Zaja, Giovanni D'Arena, Jacopo Olivieri, Silvia Rasi, Abdurraouf Mahmoud, Wael Al Essa, Bassel Awikeh, Sreekar Kogila, Matteo Bellia, Samir Mouhssine, Paolo Sportoletti, Roberto Marasca, Lydia Scarfo, Paolo Ghia, Valter Gattei, Robin Foa, Davide Rossi, Gianluca Gaidano
Summary: XPO1 mutations in CLL were found to be associated with increased binding sites for transcription factors regulated by pathways emanating from the B-cell receptor. These mutations also resulted in transcriptomic features associated with BCR and cytokine signalling. In a study of 957 early-stage CLL cases, XPO1 mutations were identified as a novel predictor of shorter time to first treatment, independent of immunoglobulin status and early-stage prognostic models.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Dermatology
N. Loft, A. Egeberg, M. K. Rasmussen, L. E. Bryld, C. Nissen, T. N. Dam, K. K. Ajgeiy, L. Iversen, L. Skov
Summary: This study aims to identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment. The results showed that treatment refractory patients had higher body weight, while super-responders had fewer comorbidities and higher socioeconomic status.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Hematology
Matilde Slot, Carsten Utoft Niemann, Lars Holger Ehlers, Emelie Curovic Rotbain
Summary: This study aimed to assess the cost-effectiveness of venetoclax + obinutuzumab (VenO), chlorambucil + obinutuzumab (ClbO), and ibrutinib in the treatment of treatment-naive CLL patients in Denmark. The results showed that VenO was cost-effective, with an incremental cost-effectiveness ratio (ICER) of euro9491 per QALY gained. On the other hand, compared with VenO, ibrutinib had a higher ICER of euro302 156 per QALY and was not considered cost-effective in Danish healthcare.
Review
Oncology
Moritz Bewarder, Stephan Stilgenbauer, Lorenz Thurner, Dominic Kaddu-Mulindwa
Summary: Standard treatment for chronic lymphocytic leukemia (CLL) has shifted towards the use of novel agents such as BTK inhibitors, Bcl-2 inhibitors, and PI3K inhibitors, which have shown effectiveness in treating CLL. Despite these advancements, there is ongoing exploration for new therapeutic approaches and the challenge of determining the optimal combination and sequence of treatments.
Review
Cardiac & Cardiovascular Systems
Amr Abdin, Stefan D. Anker, Javed Butler, Andrew J. Stewart Coats, Ingrid Kindermann, Mitja Lainscak, Lars H. Lund, Marco Metra, Wilfried Mullens, Giuseppe Rosano, Jonathan Slawik, Jan Wintrich, Michael Boehm
Summary: Timely diagnosis and treatment are crucial for the prognosis of patients with acute HF, and early and intensive treatment in the post-worsening HF period may reduce rates of early readmission and mortality.
Review
Cardiac & Cardiovascular Systems
Amr Abdin, Stefan D. Anker, Javed Butler, Andrew J. Stewart Coats, Ingrid Kindermann, Mitja Lainscak, Lars H. Lund, Marco Metra, Wilfried Mullens, Giuseppe Rosano, Jonathan Slawik, Jan Wintrich, Michael Boehm
Summary: In patients with heart failure, acute decompensation can occur rapidly and has a poor prognosis comparable to acute myocardial infarction. Therefore, timely diagnosis and immediate treatment are crucial for improving outcomes.
Article
Oncology
Stefan Norin, Bo Bjorkstrand, Franz Rommel, Lars Timberg, Per-Ola Andersson, Johan Haggstrom, Anders Aldrin, Lotta Hansson
Article
Oncology
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Hakan Mellstedt, Anders Osterborg, Jeanette Lundin
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2017)
Article
Hematology
Maria Winqvist, Anna Asklid, P. O. Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Osterborg
Article
Hematology
Marzia Palma, Giusy Gentilcore, Kia Heimersson, Fariba Mozaffari, Barbro Nasman-Glaser, Emma Young, Richard Rosenquist, Lotta Hansson, Anders Osterborg, Hakan Mellstedt
Letter
Oncology
Anna Asklid, Maria Winqvist, Sandra Eketorp Sylvan, Agnes Mattsson, Einar Bjorgvinsson, Frans Soltoft, Johanna Repits, Joris Diels, Anders Osterborg, Lotta Hansson
LEUKEMIA & LYMPHOMA
(2017)
Article
Oncology
Abdul Salam Khan, Mohammad Hojjat-Farsangi, Amir Hossein Daneshmanesh, Lotta Hansson, Parviz Kokhaei, Anders Osterborg, Hakan Mellstedt, Ali Moshfegh
Article
Hematology
Maria Winqvist, Anna Asklid, P. O. Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Osterborg
Article
Hematology
Marzia Palma, Giusy Gentilcore, Kia Heimersson, Fariba Mozaffari, Barbro Nasman-Glaser, Emma Young, Richard Rosenquist, Lotta Hansson, Anders Osterborg, Hakan Mellstedt
Article
Hematology
Marzia Palma, Lotta Hansson, Tom A. Mulder, Lars Adamson, Barbro Nasman-Glaser, Ingrid Eriksson, Kia Heimersson, Harriet Ryblom, Fariba Mozaffari, Ann Svensson, Giusy Gentilcore, Anders Osterborg, Hakan Mellstedt
EUROPEAN JOURNAL OF HAEMATOLOGY
(2018)
Article
Hematology
S. Eketorp Sylvan, J. Lundin, M. Ipek, M. Palma, C. Karlsson, L. Hansson
ANNALS OF HEMATOLOGY
(2014)
Article
Oncology
Shahryar Kiaii, Parviz Kokhaei, Fariba Mozaffari, Eva Rossmann, Fatemeh Pak, Ali Moshfegh, Marzia Palma, Lotta Hansson, Kaveh Mashayekhi, Mohammad Hojjat-Farsangi, Anders Osterborg, Aniruddha Choudhury, Hakan Mellstedt
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2013)
Article
Multidisciplinary Sciences
Mohammad Hojjat-Farsangi, Mahmood Jeddi-Tehrani, Amir Hossein Daneshmanesh, Fariba Mozaffari, Ali Moshfegh, Lotta Hansson, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Hodjattallah Rabbani, Anders Osterborg, Hakan Mellstedt, Fazel Shokri
Article
Hematology
Maria L. Andersson, Hemming Johansson, Anders Osterborg, Agneta Mansson-Broberg, Lotta Hansson, Marzia Palma
Summary: This retrospective study analyzed the incidence of cardiovascular side effects, particularly atrial fibrillation and hypertension, as well as bleeding events during long-term follow-up in patients with chronic lymphocytic leukemia treated with ibrutinib. Among 110 patients with no prior history of AF, 24.5% were diagnosed during treatment. Newly diagnosed or worsening hypertension occurred in 15.7% of the patients. Treatment discontinuation and dose reduction occurred in 68% and 47% of the patients, respectively.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Lotta Hansson, Anna Asklid, Joris Diels, Sandra Eketorp-Sylvan, Johanna Repits, Frans Soltoft, Ulrich Jaeger, Anders Osterborg
ANNALS OF HEMATOLOGY
(2017)
